PD-Rx Pharmaceuticals, Inc. has recalled approximately 3,703 bottles of Metformin Hydrochloride Extended-Release (ER) USP, 500 mg tablets, a prescription medication used to manage blood sugar in patients with type 2 diabetes. The recall was initiated because FDA laboratory testing found levels of N-Nitrosodimethylamine (NDMA) that exceed the acceptable daily intake limit. Consumers who have these tablets should not stop taking their medication without first consulting a healthcare professional, as the risk of uncontrolled blood sugar may outweigh the risk of exposure to the impurity. You should contact your doctor or pharmacist to discuss alternative treatments or to receive a replacement prescription.
NDMA is classified as a probable human carcinogen, meaning it is a substance that could cause cancer with long-term exposure. While NDMA is a common environmental contaminant found in water and foods, the levels detected in these specific lots of Metformin exceed the safety thresholds established by the FDA.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.